A Phase 3 interventional study of Tenofovir DF and Placebo in HIV Infections, sponsored by Gilead Sciences. Completed at 18 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-07-14.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.
Among the 98 studies testing tenofovir in HIV Infections, this one is the 51st largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2006, is one of 16 in phase 3, and was the 43rd registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →1 of the 98 studies testing tenofovir in HIV Infections is open now. Recruiting first, the newest first:
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 26 · Phase 3 20 · Phase 4 27
First in 1999; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is close to the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 99 across the 94 interventional studies. Of the 82 that completed or were terminated, 25 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 98 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
84 studies in HIV Infections by Gilead Sciences: 2 open now, 8 under way, 4 of them phase 3. Of 71 finished, 28 (39%) have results posted.
Among the 84 studies in HIV Infections by Gilead Sciences, this one is the 46th largest by enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2006, is one of 26 in phase 3, and was the 40th registered.
Gilead Sciences’s HIV Infections studies by the year they started, since 1999.
1 of the studies testing tenofovir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06338826ANRS, Emerging Infectious DiseasesStudy Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 98 studies testing tenofovir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 84 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) plus a genotype-guided optimized background regimen (OBR) compared to placebo plus OBR in the treatment of human immunodeficiency virus type 1 (HIV-1) infected antiretroviral treatment-experienced adolescents with plasma HIV-1 ribonucleic acid (RNA) levels greater than or equal to 1000 copies/mL.
This is a 48-week, randomized, double-blind, placebo-controlled, multicenter study of the safety and efficacy of tenofovir DF as part of an optimized antiretroviral regimen in HIV-1 infected adolescents (12 years to \< 18 years of age) who are failing their current antiretroviral regimen and have HIV-1 RNA levels ≥ 1000 copies/mL at screening. Data from three consecutive 96-week study extensions have been used to evaluate the long-term efficacy, safety, and tolerability of open-label tenofovir DF as part of an antiviral regimen, providing data for up to 336 weeks of total drug exposure.
Pretreatment:
HIV-1 genotyping will be performed as part of the screening assessments to assist in the construction of an OBR, defined as at least 3, but no more than 5 antiretroviral agents, not including tenofovir DF or placebo.
Randomized Phase:
Participants will be randomized in a 1:1 ratio to receive either tenofovir DF + OBR, or placebo + OBR. The majority of efficacy and safety assessments will be performed at each clinic visit (Weeks 4, 8, 16, 24, 32, 40, and 48). At Week 24, participants who are adherent to study drug (in the opinion of the investigator), but do not demonstrate a ≥ 0.5 log10 copies/mL decrease from baseline in HIV-1 RNA, will be considered to be nonresponders and will be unblinded. Nonresponders randomized to the placebo group will be given the option to continue on study and receive open-label tenofovir DF with an appropriate background regimen determined by the investigator. Nonresponders randomized to the tenofovir DF treatment group will be discontinued from the study.
Extension Phases:
After completing 48 weeks of double-blind treatment with tenofovir DF or placebo, participants who have not reached 18 years of age, and who, in the opinion of the investigator, would derive clinical benefit from the use of open-label tenofovir DF, will be given the option to continue (or initiate) treatment with open-label tenofovir DF in the first of three 96 week study extension periods. Nonresponders who receive open-label tenofovir DF after Week 24 will also be considered eligible for the first study extension if they met the above criteria at Week 48.
After completing the first 96 week study extension, participants who have not reached 18 years of age, and who have shown ongoing clinical benefit from tenofovir DF, will be given the option to continue receiving open-label tenofovir DF for an additional 96 weeks or until tenofovir DF became commercially available in the country where the participants are enrolled, whichever occurs first.
After completing the second 96 week study extension, participants who have not reached 18 years of age, and who have shown ongoing clinical benefit from tenofovir DF, will be given the option to continue receiving open-label tenofovir DF for an additional 96 weeks or until tenofovir DF became commercially available in the country where the participants are enrolled, whichever occurs first.
Presentation of data:
After the randomized phase of the study, participants randomized to placebo during the randomized phase of the study and then switch to open-label tenofovir DF will have their baseline reset (defined as open-label baseline), and only outcome data collected after (on/after for adverse events (AEs)/concomitant medications) participants receive their first dose of open-label tenofovir DF will be included.
Major Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tenofovir DF administered orally, one tablet daily without regard to meals
Drug: Tenofovir DF
Placebo to match tenofovir DF administered orally, one tablet daily without regard to meals
Drug: Placebo
Tenofovir DF 300-mg tablet, administered orally, daily + OBR
Tenofovir DF Placebo administered orally, daily + OBR
Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA
DAVG24 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 24 minus the baseline value. DAVG24 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value. Data for participants who discontinued the randomized (double-blind) phase of the study early were included up until the point of study discontinuation (missing data not imputed).
Time frame: Baseline to 24 Weeks
Time-weighted Average Change From Baseline Through Week 48 (DAVG48) in Plasma HIV-1 RNA
DAVG48 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 48 minus the baseline value. DAVG48 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value. Data for participants who discontinued the double-blind phase of the study early were included up until the point of discontinuation from the study (ie, missing data were not imputed).
Time frame: Baseline to 48 weeks
Change From Baseline to Week 24 in HIV-1 RNA
Time frame: Baseline to 24 weeks
Change From Baseline to Week 48 in HIV-1 RNA
Time frame: Baseline to 48 weeks
Change From Baseline to Week 96 in HIV-1 RNA
Time frame: Baseline to 96 weeks
Change From Baseline to Week 144 in HIV-1 RNA
Time frame: Baseline to 144 weeks
Change From Baseline to Week 192 in HIV-1 RNA
Time frame: Baseline to 192 weeks
Change From Baseline to Week 240 in HIV-1 RNA
Time frame: Baseline to 240 weeks
Change From Baseline to Week 288 in HIV-1 RNA
Time frame: Baseline to 288 weeks
Change From Baseline to Week 336 in HIV-1 RNA
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
Time frame: Baseline to 336 weeks
Change From Baseline to Week 24 in Cluster Determinant 4 (CD4) Count
Time frame: Baseline to 24 weeks
Change From Baseline to Week 48 in CD4 Count
Time frame: Baseline to 48 weeks
Change From Baseline to Week 96 in CD4 Count
Time frame: Baseline to 96 weeks
Change From Baseline to Week 144 in CD4 Count
Time frame: Baseline to 144 weeks
Change From Baseline to Week 192 in CD4 Count
Time frame: Baseline to 192 weeks
Change From Baseline to Week 240 in CD4 Count
Time frame: Baseline to 240 weeks
Change From Baseline to Week 288 in CD4 Count
Time frame: Baseline to 288 weeks
Change From Baseline to Week 336 in CD4 Count
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
Time frame: Baseline to 336 weeks
Change From Baseline to Week 24 in CD4 Percentage
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
Time frame: Baseline to 24 weeks
Change From Baseline to Week 48 in CD4 Percentage
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
Time frame: Baseline to 48 weeks
Change From Baseline to Week 96 in CD4 Percentage
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
Time frame: Baseline to 96 weeks
Change From Baseline to Week 144 in CD4 Percentage
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
Time frame: Baseline to 144 weeks
Change From Baseline to Week 192 in CD4 Percentage
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
Time frame: Baseline to 192 weeks
Change From Baseline to Week 240 in CD4 Percentage
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
Time frame: Baseline to 240 weeks
Change From Baseline to Week 288 in CD4 Percentage
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
Time frame: Baseline to 288 weeks
Change From Baseline to Week 336 in CD4 Percentage
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
Time frame: Baseline to 336 weeks
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 24
Time frame: Baseline to 24 weeks
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 48
Time frame: Baseline to 48 weeks
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 96
Time frame: Baseline to 96 weeks
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 144
Time frame: Baseline to 144 weeks
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 192
Time frame: Baseline to 192 weeks
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 240
Time frame: Baseline to 240 weeks
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0log 10 Copies/mL From Baseline to Week 288
Time frame: Baseline to 288 weeks
Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 336
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
Time frame: Baseline to 336 weeks
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 24
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96
Time frame: Week 96
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144
Time frame: Week 144
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 192
Time frame: Week 192
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 240
Time frame: Week 240
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 288
Time frame: Week 288
Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 336
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
Time frame: Week 336
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
Time frame: Week 96
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144
Time frame: Week 144
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 192
Time frame: Week 192
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 240
Time frame: Week 240
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 288
Time frame: Week 288
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 336
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
Time frame: Week 336
Percentage of Participants With Virologic Failure Through Week 48
Virologic failure was defined as either nonresponse or viral rebound. * Nonresponse (failure to achieve response). Response was defined as either * A ≥ 0.5 log10 copies/mL decrease in HIV-1 RNA from baseline at 2 consecutive visits, or * HIV-1 RNA \< 400 copies/mL at 2 consecutive visits. * Viral rebound was defined as either * Participants who achieved a ≥ 0.5 log10 copies/mL decrease from baseline in plasma HIV-1 RNA at 2 consecutive visits, who then subsequently achieved plasma HIV-1 RNA values ≥ 1.0 log10 copies/mL above their on-study nadir (lowest value) and/or plasma HIV-1 RNA values ≥ the baseline value at 2 consecutive visits, or * Participants who achieved plasma HIV-1 RNA levels of \< 400 copies/mL at 2 consecutive visits, and then subsequently had plasma HIV-1 RNA levels \> 1000 copies/mL at 2 consecutive visits. The virologic failure rate was estimated from Kaplan-Meier product limit method by including all HIV-1 RNA data collected during the double-blind phase.
Time frame: Up to 48 weeks
There were 17 sites in Brazil and 1 site in Panama. First participant was screened on 13 June 2006. The last study visit occurred on 19 December 2013.
| Milestone | Tenofovir DF | Placebo |
|---|---|---|
| Started | 45 | 42 |
| Completed | 27 | 29 |
| Not completed | 18 | 13 |
| Withdrew: Virologic failure | 14 | 10 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Intolerance to antiretroviral regimen | 1 | 0 |
| Milestone | Tenofovir DF | Placebo |
|---|---|---|
| Started | 24 | 36 |
| Completed | 12 | 19 |
| Not completed | 12 | 17 |
| Withdrew: Physician decision | 9 | 13 |
| Withdrew: Lack of efficacy | 1 | 4 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | Tenofovir DF | Placebo |
|---|---|---|
| Started | 9 | 14 |
| Completed | 4 | 9 |
| Not completed | 5 | 5 |
| Withdrew: Physician decision | 4 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Milestone | Tenofovir DF | Placebo |
|---|---|---|
| Started | 1 | 4 |
| Completed | 0 | 2 |
| Not completed | 1 | 2 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
DAVG24 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 24 minus the baseline value. DAVG24 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value. Data for participants who discontinued the randomized (double-blind) phase of the study early were included up until the point of study discontinuation (missing data not imputed).
| log10 copies/mL | Tenofovir DF | Placebo |
|---|---|---|
| Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA | -1.580 (-2.15 to -0.27) | -1.549 (-2.36 to -0.34) |
DAVG48 was defined as the time-weighted average between the first postbaseline value through the last value up to Week 48 minus the baseline value. DAVG48 was calculated using the trapezoidal rule with all available postbaseline data minus the baseline value. Data for participants who discontinued the double-blind phase of the study early were included up until the point of discontinuation from the study (ie, missing data were not imputed).
| log10 copies/mL | Tenofovir DF | Placebo |
|---|---|---|
| Time-weighted Average Change From Baseline Through Week 48 (DAVG48) in Plasma HIV-1 RNA | -1.423 (-2.25 to -0.25) | -1.352 (-2.72 to -0.53) |
| log10 copies/mL | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Change From Baseline to Week 24 in HIV-1 RNA | -1.23 (-2.3 to -0.1) | -1.27 (-2.8 to -0.1) | 0.0 (0.0 to 0.0) | -0.1 (-0.6 to 0.3) |
| log10 copies/mL | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Change From Baseline to Week 48 in HIV-1 RNA | -0.97 (-2.3 to 0.0) | -1.53 (-3.0 to 0.0) | 0.0 (0.0 to 0.6) | 0.2 (-0.1 to 0.5) |
| log10 copies/mL | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 96 in HIV-1 RNA | -2.1 (-2.5 to -0.6) | 0.0 (0.0 to 0.9) | 0.1 (-1.4 to 0.8) |
| log10 copies/mL | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 144 in HIV-1 RNA | -2.5 (-2.7 to -2.2) | 0.2 (0.0 to 1.6) | 0.7 (0.6 to 0.8) |
| log10 copies/mL | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 192 in HIV-1 RNA | -2.0 (-2.5 to -0.7) | 0.0 (0.0 to 0.2) | -0.1 (-1.4 to 1.3) |
| log10 copies/mL | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 240 in HIV-1 RNA | -2.5 (-2.6 to -2.2) | -0.4 (-0.8 to 0.0) | -1.4 (-1.4 to -1.4) |
| log10 copies/mL | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 288 in HIV-1 RNA | -1.1 (-1.1 to -1.1) | -0.8 (-0.8 to -0.8) | 0.6 (0.6 to 0.6) |
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
No measurements were reported for this outcome.
| cells/mm3 | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Change From Baseline to Week 24 in Cluster Determinant 4 (CD4) Count | 69 (-26 to 172) | 49 (-3 to 156) | -43 (-181 to 53) | -12 (-48 to 59) |
| cells/mm3 | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Change From Baseline to Week 48 in CD4 Count | 152 (-4 to 241) | 148 (42 to 289) | 15 (-69 to 95) | -47 (-83 to 67) |
| cells/mm3 | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 96 in CD4 Count | 152 (52 to 266) | -6 (-96 to 85) | -69 (-75 to 278) |
| cells/mm^3 | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 144 in CD4 Count | 188 (53 to 361) | -88 (-165 to 93) | 33 (-109 to 174) |
| cells/mm^3 | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 192 in CD4 Count | 166 (-82 to 333) | -70 (-155 to 220) | -23 (-46 to 1) |
| cells/mm^3 | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 240 in CD4 Count | 221 (59 to 368) | 571 (-13 to 1155) | 258 (258 to 258) |
| cells/mm^3 | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 288 in CD4 Count | 310 (310 to 310) | 100 (100 to 100) | 309 (309 to 309) |
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
No measurements were reported for this outcome.
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
| Percentage of CD4 lymphocytes | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Change From Baseline to Week 24 in CD4 Percentage | 3.0 (0.0 to 6.0) | 2.0 (-1.0 to 4.0) | 0.0 (-3.0 to 3.0) | -1.0 (-3.0 to 2.0) |
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
| Percentage of CD4 lymphocytes | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Change From Baseline to Week 48 in CD4 Percentage | 6.0 (2.5 to 9.0) | 5.0 (2.0 to 8.0) | 2.0 (1.0 to 4.0) | -1.0 (-4.0 to 7.0) |
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
| Percentage of CD4 lymphocytes | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 96 in CD4 Percentage | 5.0 (2.0 to 8.0) | 2.0 (0.0 to 5.0) | 9.0 (2.0 to 15.0) |
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
| Percentage of CD4 lymphocytes | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 144 in CD4 Percentage | 6.5 (-2.0 to 13.0) | 0.0 (-4.0 to 8.0) | 5.5 (2.0 to 9.0) |
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
| Percentage of CD4 lymphocytes | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 192 in CD4 Percentage | 5.0 (-2.0 to 11.6) | 1.9 (-1.0 to 10.0) | 4.8 (1.5 to 8.0) |
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
| Percentage of CD4 lymphocytes | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 240 in CD4 Percentage | 10.0 (-2.0 to 13.3) | 8.9 (8.2 to 9.6) | 18.9 (18.9 to 18.9) |
CD4 percentage is the percentage of total lymphocytes that are CD4 cells.
| Percentage of CD4 lymphocytes | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Change From Baseline to Week 288 in CD4 Percentage | 7.4 (7.4 to 7.4) | 4.0 (4.0 to 4.0) | 11.9 (11.9 to 11.9) |
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
No measurements were reported for this outcome.
| Percentage of participants | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 24 | 56.8 | 51.2 | 0 | 12.5 |
| Percentage of participants | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 48 | 47.7 | 53.7 | 0 | 0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 96 | 73.7 | 5.9 | 33.3 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 144 | 90.0 | 0 | 0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 192 | 71.4 | 0 | 50.0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0 log10 Copies/mL From Baseline to Week 240 | 100.0 | 0 | 100.0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With an HIV-1 RNA Decrease of ≥ 1.0log 10 Copies/mL From Baseline to Week 288 | 100.0 | 0 | 0 |
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
No measurements were reported for this outcome.
| Percentage of participants | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 24 | 40.9 | 41.5 | 83.3 | 6.3 |
| Percentage of participants | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 | 34.1 | 43.9 | 77.8 | 0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 96 | 63.2 | 70.6 | 33.3 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA >= 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 144 | 70.0 | 72.7 | 0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 192 | 57.1 | 80.0 | 50.0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 240 | 75.0 | 100.0 | 100.0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 288 | 0 | 100.0 | 0 |
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
No measurements were reported for this outcome.
| Percentage of participants | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 | 20.5 | 34.1 | 77.8 | 0 |
| Percentage of participants | Tenofovir DF | Placebo | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 | 27.3 | 36.6 | 61.1 | 0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 | 47.4 | 58.8 | 33.3 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 | 70.0 | 45.5 | 0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 192 | 42.9 | 60.0 | 50.0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 240 | 75.0 | 100.0 | 100.0 |
| Percentage of participants | Tenofovir DF | Placebo/TDF, HIV-1 RNA < 1000 Copies/mL | Placebo/TDF, HIV-1 RNA ≥ 1000 Copies/mL |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 288 | 0 | 100.0 | 0 |
No analysis was performed because the last study participant discontinued after Week 294 and the study was closed.
No measurements were reported for this outcome.
Virologic failure was defined as either nonresponse or viral rebound. * Nonresponse (failure to achieve response). Response was defined as either * A ≥ 0.5 log10 copies/mL decrease in HIV-1 RNA from baseline at 2 consecutive visits, or * HIV-1 RNA \< 400 copies/mL at 2 consecutive visits. * Viral rebound was defined as either * Participants who achieved a ≥ 0.5 log10 copies/mL decrease from baseline in plasma HIV-1 RNA at 2 consecutive visits, who then subsequently achieved plasma HIV-1 RNA values ≥ 1.0 log10 copies/mL above their on-study nadir (lowest value) and/or plasma HIV-1 RNA values ≥ the baseline value at 2 consecutive visits, or * Participants who achieved plasma HIV-1 RNA levels of \< 400 copies/mL at 2 consecutive visits, and then subsequently had plasma HIV-1 RNA levels \> 1000 copies/mL at 2 consecutive visits. The virologic failure rate was estimated from Kaplan-Meier product limit method by including all HIV-1 RNA data collected during the double-blind phase.
| Kaplan-Meier percentage | Tenofovir DF | Placebo |
|---|---|---|
| Percentage of Participants With Virologic Failure Through Week 48 | 51 | 39 |
Collected over Up to Week 294 plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenofovir DF | — | 10/45 (22.2%) | 44/45 (97.8%) |
| Placebo | — | 3/42 (7.1%) | 35/42 (83.3%) |
| All TDF | — | 20/81 (24.7%) | 76/81 (93.8%) |
| Event | Tenofovir DF | Placebo | All TDF |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/45 | 1/42 | 5/81 |
| SinusitisInfections and infestations | 2/45 | 0/42 | 2/81 |
| Pneumocystis Jiroveci PneumoniaInfections and infestations | 2/45 | 0/42 | 2/81 |
| Herpes ZosterInfections and infestations | 0/45 | 0/42 | 3/81 |
| CellulitisInfections and infestations | 0/45 | 1/42 | 0/81 |
| Cerebral ToxoplasmosisInfections and infestations | 0/45 | 1/42 | 0/81 |
| MastoiditisInfections and infestations | 0/45 | 1/42 | 0/81 |
| CryptococcosisInfections and infestations | 1/45 | 0/42 | 1/81 |
| GastroenteritisInfections and infestations | 1/45 | 0/42 | 1/81 |
| Respiratory Tract InfectionInfections and infestations | 1/45 | 0/42 | 1/81 |
| Event | Tenofovir DF | Placebo | All TDF |
|---|---|---|---|
| VomitingGastrointestinal disorders | 16/45 | 5/42 | 21/81 |
| SinusitisInfections and infestations | 12/45 | 6/42 | 24/81 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/45 | 6/42 | 24/81 |
| NauseaGastrointestinal disorders | 11/45 | 3/42 | 15/81 |
| DiarrhoeaGastrointestinal disorders | 10/45 | 4/42 | 17/81 |
| NasopharyngitisInfections and infestations | 8/45 | 7/42 | 18/81 |
| Upper Respiratory Tract InfectionInfections and infestations | 8/45 | 3/42 | 17/81 |
| HeadacheNervous system disorders | 6/45 | 5/42 | 16/81 |
| Abdominal PainGastrointestinal disorders | 8/45 | 5/42 | 9/81 |
| DizzinessNervous system disorders | 8/45 | 5/42 | 11/81 |
Safety Analysis Set: participants were randomized and received at least 1 dose of study medication.
| Age, Categorical(Participants) | Tenofovir DF | Placebo | Total |
|---|---|---|---|
| <=18 years | 45 | 42 | 87 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Tenofovir DF | Placebo | Total |
|---|---|---|---|
| Mean | 14 ± 1.5 | 14 ± 1.5 | 14 ± 1.5 |
| Sex: Female, Male(Participants) | Tenofovir DF | Placebo | Total |
|---|---|---|---|
| Female | 24 | 25 | 49 |
| Male | 21 | 17 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Tenofovir DF | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 45 | 42 | 87 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Tenofovir DF | Placebo | Total |
|---|---|---|---|
| White | 23 | 22 | 45 |
| Black or African Heritage | 14 | 11 | 25 |
| Mulatto | 4 | 4 | 8 |
| Mixed Race | 1 | 2 | 3 |
| Indian Descendant | 1 | 1 | 2 |
| Mestizo | 0 | 2 | 2 |
| Black and White Race | 1 | 0 | 1 |
| South American Indian | 1 | 0 | 1 |
| Region of Enrollment(participants) | Tenofovir DF | Placebo | Total |
|---|---|---|---|
| Panama | 2 | 2 | 4 |
| Brazil | 43 | 40 | 83 |
| Body Mass Index(kg/m^2) | Tenofovir DF | Placebo | Total |
|---|---|---|---|
| Mean | 18.72 ± 2.304 | 19.99 ± 3.238 | 19.33 ± 2.849 |
| CD4 Cell Count(cells/mm^3) | Tenofovir DF | Placebo | Total |
|---|---|---|---|
| Mean | 390 ± 244.0 | 357 ± 200.8 | 374 ± 223.5 |
4 further baseline measures are reported on the registry.
The record gives a start of Jun 2006, a primary completion of Sep 2008 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir